Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Breast Cancer Metastatic × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Breast Neoplasms 8 Prostatic Neoplasms 5 Small Cell Lung Carcinoma 4 Stomach Neoplasms 3 Neoplasms 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Metastatic Castration-Resistant Prostate Cancer 1 Male Urogenital Diseases 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Glioma 1 Genital Neoplasms, Male 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

pyrotinib 1 patritumab deruxtecan 1 olaparib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06298084 2024-03-29

ICARUSBREAST02

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡